Skip to main content

Table 5 Cost-effectiveness of screening compared to no screening under various survival scenarios

From: The cost-effectiveness of neonatal screening for Cystic Fibrosis: an analysis of alternative scenarios using a decision model

Scenario: Conservative survivala Balanced survivala Optimistic survivala
Model parameter:    
   % surviving to age 16 90% 95% 97%
   % surviving to age 30 72% 84% 90%
   % surviving to age 50 30% 45% 55%
   Median survival (years) 41 48 52
   Mean survival (years) 39.4 45.8 49.9
Mean years spent:    
   before symptoms emerge 1.0 1.0 1.0
   with symptoms 32.3 38.7 42.8
   in severe irreversible stage 6.1 6.1 6.1
Incremental C/E ratio (£/QALY) £7,474 £6,864 £6,532
  1. a Under late diagnosis assumptions